NASDAQ · DHR
Healthcare · Medical - Diagnostics & Research
$232.23
Down-$4.75 (-2.00%)
Updated Oct 31, 2026, 5:41 PM
SID Score
6.1/10
Composite research score
Smart Money
47/100
Neutral
Price performance · DHR
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
DHR closed at $232.23 after 21 trading sessions, up 8.49% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $238.46 | $238.46 | $230.46 | $232.23 | 3.76M |
| Oct 29, 2026 | $234.00 | $237.62 | $232.86 | $236.98 | 2.7M |
| Oct 28, 2026 | $231.00 | $238.03 | $229.55 | $234.07 | 3.14M |
| Oct 27, 2026 | $231.00 | $234.00 | $229.3201 | $232.00 | 2.5M |
| Oct 26, 2026 | $230.94 | $233.95 | $230.60 | $232.97 | 3.12M |
| Oct 23, 2026 | $229.17 | $230.66 | $225.60 | $230.50 | 3.94M |
| Oct 22, 2026 | $233.80 | $238.128 | $228.165 | $229.75 | 7.07M |
| Oct 21, 2026 | $217.56 | $234.40 | $217.55 | $233.86 | 8.9M |
| Oct 20, 2026 | $225.75 | $227.78 | $222.65 | $224.24 | 9.52M |
| Oct 19, 2026 | $229.01 | $230.57 | $223.26 | $224.43 | 4.14M |
| Oct 16, 2026 | $230.50 | $231.925 | $228.36 | $229.04 | 3.52M |
| Oct 15, 2026 | $228.21 | $233.02 | $226.7201 | $231.50 | 5.13M |
| Oct 14, 2026 | $225.00 | $227.855 | $222.74 | $224.69 | 3.6M |
| Oct 13, 2026 | $222.25 | $225.705 | $219.225 | $222.84 | 6.01M |
| Oct 12, 2026 | $220.72 | $221.42 | $219.11 | $221.20 | 3M |
| Oct 9, 2026 | $216.91 | $220.86 | $216.51 | $219.81 | 3.93M |
| Oct 8, 2026 | $217.40 | $218.23 | $211.715 | $217.46 | 5.29M |
| Oct 7, 2026 | $217.77 | $220.48 | $214.39 | $218.49 | 3.97M |
| Oct 6, 2026 | $223.50 | $227.61 | $215.09 | $215.61 | 3.64M |
| Oct 5, 2026 | $213.81 | $222.15 | $213.44 | $221.21 | 3.09M |
| Oct 2, 2026 | $213.40 | $216.0594 | $211.9801 | $214.06 | 3.92M |
The latest Smart Investors Daily articles mentioning DHR.
Company
Market Activity
Research & News
DHR research
Company profile and research snapshot.
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life sciences and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 22, 2026 | Stifel | Buy | — |
| Oct 22, 2026 | TD Cowen | Buy | — |
| Oct 22, 2026 | JP Morgan | Overweight | — |
| Oct 22, 2026 | Baird | Outperform | — |
| Oct 22, 2026 | Barclays | Overweight | — |
Generated Oct 31, 2026, 3:16 PM
Danaher Corporation declined 2.00% ($4.75) today amid a broader market reassessment of life sciences and diagnostics companies facing tariff headwinds. While recent headlines don't indicate company-specific negative news, the stock appears caught in sector-wide pressure as investors recalibrate valuations around potential trade policy impacts on DHR's global operations.
Bottom line: Danaher's 2% decline appears driven by sector-wide tariff concerns rather than company-specific operational issues, with the stock facing near-term margin pressure from potential trade policies. Investors should monitor tariff developments and DHR's earnings guidance for any margin impact, while recognizing the company's strong competitive positioning and growth opportunities in emerging markets like reaction monitoring could support recovery once trade uncertainty diminishes.
Benzinga · Oct 30, 2026
In a new SEC filing on October 29, it was revealed that Bouda, VP at Danaher (NYSE:DHR), executed a significant exercise of company stock options. What Happened: In an insider options exercise disclosed in a Form 4
Benzinga · Oct 30, 2026
Matthew McGrew, Executive Vice President at Danaher (NYSE:DHR), reported a large exercise of company stock options on October 29, according to a new SEC filing. What Happened: In an insider options exercise disclosed in
Yahoo · Oct 29, 2026
Boost ROI by targeting pharma, portable and AI-enabled spectroscopy, rapid testing, regulatory compliance, and Asia-Pacific expansion.Dublin, Oct. 29, 2026 (GLOBE NEWSWIRE) -- "Molecular Spectroscopy - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global molecular spectroscopy market, valued at US$5.5 billion in 2025, is projected to reach US$8.7 billion by 2032, expanding at a compound annual growth rate (CAGR) of 6.7%. Growth is supported by rising
Yahoo · Oct 29, 2026
Boost ROI with real-time analytics, advanced spectroscopy and PAT to optimize yields, cut waste, prevent batch failures and strengthen process safety.Dublin, Oct. 29, 2026 (GLOBE NEWSWIRE) -- "Reaction Monitoring - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering The global reaction monitoring market, valued at US$1.6 billion in 2024, is projected to reach US$2 billion by 2030, expanding at a compound annual growth rate (CAGR) of 4.1% between 2024 and 2030. M
Interpretive context generated from the platform’s current data sources.
Danaher Corporation shares closed at $232.23, declining 1.12% in the most recent trading session, per SID market data. Despite the daily pullback, the stock has demonstrated notable strength over recent months, gaining 9.67% over the past month and 17.58% over the past three months. On a trailing twelve-month basis, however, DHR remains slightly negative at -1.84%, reflecting the broader challenges faced by the healthcare sector during that period. Technically, the stock trades above both key moving averages, sitting 6.11% above its 50-day moving average of $218.85 and 16.80% above its 200-day moving average of $198.84, according to Massive/Polygon data. The 14-day RSI reads 62.2, indicating momentum that is approaching but has not yet reached overbought territory. Danaher's beta of 0.923 confirms the stock exhibits slightly lower volatility relative to the broader market, consistent with its defensive healthcare positioning.
Danaher Corporation currently trades at a price-to-earnings ratio of 47.14, a premium valuation relative to the broader healthcare sector, per SID market data. The elevated PEG ratio of 14.87 suggests the company's earnings growth rate does not proportionally support the current P/E multiple, indicating the market may be pricing in longer-term recovery and margin expansion. The stock's price-to-book ratio stands at 3.23, reflecting the significant intangible asset base Danaher has accumulated through its acquisition-driven growth strategy, according to SEC filings. Danaher offers a modest dividend yield of approximately 0.53%, consistent with its capital allocation philosophy that prioritizes reinvestment and strategic acquisitions over shareholder distributions. The company's market capitalization of $166.5 billion positions it among the largest healthcare conglomerates globally. These valuation metrics collectively indicate that investors are paying a significant premium for Danaher's long-term compounding potential and operational excellence framework.
Danaher Corporation's composite smart money score stands at 46 out of 100, reflecting a neutral overall signal, per SID market data. Institutional positioning is the strongest component, scoring a perfect 25 out of 25, indicating robust conviction among large fund managers and pension funds holding DHR shares. In contrast, insider activity scores a relatively low 4.3 out of 25 despite elevated transaction volume, with 20 insider trades recorded over the past 90 days according to SEC Form 4 filings. Of those transactions, 11 were purchases and 9 were sales, resulting in a marginally buy-leaning insider profile. Dark pool activity scores 5.0 out of 25, suggesting limited institutional block trading through off-exchange venues. Congressional trading activity registered a moderate 12 out of 25, indicating some legislative interest in the stock. The divergence between maximal institutional ownership confidence and subdued insider conviction creates a mixed signal landscape that warrants continued monitoring through 13F institutional filings.
Danaher Corporation has established a consistent pattern of exceeding analyst expectations across its most recent quarterly results, according to company earnings reports. In the latest reported quarter, the company posted earnings per share of $2.11 against a consensus estimate of $1.92, delivering a positive surprise of $0.19, or approximately 9.9%. The prior quarter similarly beat expectations, with actual EPS of $1.94 versus estimates of $1.84, representing a $0.10 positive surprise. The quarter before that produced EPS of $2.06 against the $1.94 estimate, a $0.12 beat. Analysts currently project earnings of $1.92 per share for the upcoming quarter, per analyst estimates. The sequential decline in consensus estimates relative to the most recent actual result of $2.11 may reflect seasonality in Danaher's business mix. The sustained beat pattern across three consecutive quarters suggests conservative guidance practices and underlying operational momentum within the company's life sciences and diagnostics segments.
Wall Street consensus on Danaher Corporation remains uniformly positive, with all five most recent analyst updates reaffirming bullish ratings, per Wall Street analyst reports. On October 22, 2026, following the company's earnings release, Stifel and TD Cowen both maintained Buy ratings, while JP Morgan reiterated its Overweight stance, according to SID consensus data. Baird maintained its Outperform rating, and Barclays also reiterated an Overweight designation on the same date. Notably, none of the five analysts changed their prior ratings, indicating sustained conviction rather than a reactionary upgrade cycle. The unanimity across major sell-side firms spanning boutique research houses like Stifel and Baird as well as bulge-bracket institutions like JP Morgan and Barclays is particularly significant. This convergence of bullish sentiment suggests broad institutional confidence in Danaher's strategic direction, including its Danaher Business System methodology and post-separation portfolio following the Veralto spinoff. No downgrades or neutral initiations were recorded among recent coverage updates.
The latest Smart Investors Daily articles mentioning DHR.
